Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$564.59 -1.4%	$563.91	$457.42 ▼ $678.21	$34.55B	0.37	331,501 shs	336,884 shs
ONC BeOne Medicines	$294.55 +1.4%	$250.96	$152.81 ▼ $300.00	$32.28B	0.28	355,827 shs	893,521 shs
PFE Pfizer	$24.46 -0.5%	$24.07	$20.92 ▼ $31.54	$139.12B	0.58	41.96 million shs	36.27 million shs
VTRS Viatris	$8.88 -4.2%	$8.88	$6.85 ▼ $13.55	$10.42B	0.89	11.00 million shs	9.92 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+0.78%	+4.96%	-5.30%	+21.83%
ONC BeOne Medicines	0.00%	+17.68%	+16.52%	+27.52%	+29,454,999,900.00%
PFE Pfizer	0.00%	-4.64%	+2.45%	+10.53%	-18.52%
VTRS Viatris	0.00%	-2.63%	+1.25%	+17.46%	-25.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	4.4796 of 5 stars	4.5	3.0	0.0	0.0	3.9	1.7	2.5
ONC BeOne Medicines	2.6364 of 5 stars	3.5	0.0	0.0	0.0	3.1	1.7	0.6
PFE Pfizer	4.9694 of 5 stars	3.2	3.0	4.2	4.5	3.3	1.7	3.1
VTRS Viatris	3.0086 of 5 stars	1.9	4.0	2.5	0.0	2.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.10	Buy	$728.06	28.95% Upside
ONC BeOne Medicines	3.00	Buy	$327.56	11.21% Upside
PFE Pfizer	2.45	Hold	$28.55	16.72% Upside
VTRS Viatris	1.80	Reduce	$10.40	17.12% Upside

Current Analyst Ratings Breakdown

Latest VTRS, PFE, ARGX, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$321.00 ➝ $345.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$311.00 ➝ $349.00
7/8/2025	ARGX argenex	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
7/3/2025	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$700.00
7/1/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
6/24/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/11/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/10/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	15.34	$2.97 per share	190.07	$90.49 per share	6.24
ONC BeOne Medicines	$3.81B	8.47	N/A	N/A	$34.10 per share	8.64
PFE Pfizer	$63.63B	2.19	$4.36 per share	5.61	$15.62 per share	1.57
VTRS Viatris	$14.33B	0.73	$5.10 per share	1.74	$15.61 per share	0.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$16.21	34.83	52.04	0.98	40.20%	16.15%	14.33%	7/31/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	414.86	N/A	-9.40%	-7.55%	-4.42%	8/6/2025 (Confirmed)
PFE Pfizer	$8.03B	$1.38	17.72	8.07	0.89	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
VTRS Viatris	-$634.20M	-$3.17	N/A	3.46	N/A	-26.45%	16.20%	7.01%	8/7/2025 (Estimated)

Latest VTRS, PFE, ARGX, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	VTRS Viatris	$0.56	N/A	N/A	N/A	$3.46 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/31/2025	Q2 2025	ARGX argenex	$2.87	N/A	N/A	N/A	$776.82 million	N/A
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q1 2025	VTRS Viatris	$0.49	$0.50	+$0.01	-$2.55	$3.30 billion	$3.25 billion
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.03%	N/A	124.64%	16 Years
VTRS Viatris	$0.48	5.41%	N/A	N/A	N/A

Latest VTRS, PFE, ARGX, and ONC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
5/5/2025	VTRS Viatris	quarterly	$0.12	5.55%	5/23/2025	5/23/2025	6/16/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	7.29	6.68
ONC BeOne Medicines	0.05	1.96	1.71
PFE Pfizer	0.64	1.26	0.96
VTRS Viatris	1.02	1.68	0.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
ONC BeOne Medicines	48.55%
PFE Pfizer	68.36%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
ONC BeOne Medicines	6.62%
PFE Pfizer	0.06%
VTRS Viatris	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
VTRS Viatris	32,000	1.17 billion	1.17 billion	Optionable

VTRS, PFE, ARGX, and ONC Headlines

Recent News About These Companies

Viatris Inc.: Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

July 18 at 4:26 PM | finanznachrichten.de

Why Viatris (VTRS) Stock Is Falling Today

July 18 at 4:26 PM | msn.com

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

July 18 at 2:17 PM | benzinga.com

Viatris eye ointment fails late-stage study for eye condition, shares fall

July 18 at 11:26 AM | msn.com

Viatris eye ointment fails late-stage study, shares fall

July 18 at 11:26 AM | reuters.com

Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal

July 18 at 11:26 AM | msn.com

Viatris down on late-stage trial setback for eye disorder therapy

July 18 at 11:26 AM | msn.com

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

July 18 at 8:47 AM | barrons.com

Viatris eye therapy fails to meet late-stage trial goal

July 18 at 7:07 AM | reuters.com

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

July 18 at 6:59 AM | prnewswire.com

Viatris (VTRS) Announces Positive Top-line Results from VEGA-3

July 17 at 4:29 AM | finance.yahoo.com

Viatris: A Contrarian Bet With Virtually No Downside

July 16, 2025 | seekingalpha.com

Viatris Certified as a Great Place to Work® in Canada

July 15, 2025 | finance.yahoo.com

13 Best Low Priced Pharma Stocks to Buy Now

July 15, 2025 | insidermonkey.com

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma

July 15, 2025 | finance.yahoo.com

Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT

July 11, 2025 | insidermonkey.com

J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug

July 9, 2025 | msn.com

The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call

June 27, 2025 | msn.com

Viatris Inc.: Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

June 26, 2025 | finanznachrichten.de

Theravance higher as China approves Viatris-partnered COPD therapy

June 26, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

VTRS, PFE, ARGX, and ONC Company Descriptions

argenex NASDAQ:ARGX

$564.59 -8.12 (-1.42%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$564.54 -0.06 (-0.01%)

As of 07/18/2025 05:15 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BeOne Medicines NASDAQ:ONC

$294.55 +4.20 (+1.45%)

As of 07/18/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$24.46 -0.12 (-0.49%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$24.50 +0.04 (+0.16%)

As of 07/18/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Viatris NASDAQ:VTRS

$8.88 -0.39 (-4.21%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.94 +0.05 (+0.62%)

As of 07/18/2025 07:36 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time